Company News

IBI has recently completed the acquisition of NuPep!

January 27, 2020
corticalis ibi

IBI has recently completed the acquisition of NuPep!

IBI has recently completed the acquisition, from the Norwegian company Corticalis, of the patents bundle on “consensus peptides”, commercially traded under the name “NuPep”.

In brief, NuPeps are a library of synthetic intrinsically disordered peptides, first in class having being granted a patent on, that possess signaling properties useful in various tissues regeneration applications.

“This technological platform well complements IBI’s portfolio and allows us to further expand our researches and developments towards next generation of orthobiologics and new regenerative medicine products too”, commented Prof. Dr. Giuseppe Perale, IBI executive Vice President for clinical and scientific affairs and one of the company founders.

Today we Meet – Interview to Dr. Latorre...

Today we Meet – Interview to Dr. Latorre Valenzuela Hi Dr. Latorre!...

TODAY WE MEET – Interview to Felice,...

Today we Meet
TODAY WE MEET – Interview to Felice, Quality Control Manager Hi Felice,...

L-PRF and platelet concentrates in regenerative...

L-PRF and platelet concentrates in regenerative surgery: Theory, operational protocols, practical workshops,...

Subscribe to our newsletter